Base de dados : MEDLINE
Pesquisa : D04.210.500.745.745.654.570 [Categoria DeCS]
Referências encontradas : 46 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 5 ir para página              

  1 / 46 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27188744
[Au] Autor:Zhou W; Zhu L; Zhou H; Shen K; Lang J; Cui Q; Shi H
[Ad] Endereço:Chinese Academy of Medical Sciences Department of Pathology, Peking Union Medical College Hospital Beijing China.
[Ti] Título:The efficacy of high-intensity, focused ultrasound treatment for non-neoplastic epithelial disorders of the vulva.
[So] Source:Cell Mol Biol (Noisy-le-grand);62(4):111-5, 2016 Apr 30.
[Is] ISSN:1165-158X
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Non-neoplastic epithelial disorders of the vulva (NNEDV) are common types of vulval lesions. Although corticosteroids represent a first-line treatment for NNEDV, concerns exist about the safety associated with long-term topical corticosteroid use. Recently, several clinical trials have identified high-intensity focused ultrasound (HIFU) as a promising treatment modality for NNEDV. The aim of this multi-center, randomized, controlled clinical trial was to investigate the efficacy of HIFU therapy in women with NNEDV based on histological alterations. We enrolled patients who were clinically diagnosed with NNEDV. They were randomized into 2 treatment groups: 1) halcinonide for 3 months or 2) HIFU once. A total of 123 patients were biopsied both prior to and after the therapy, and 62 and 61 patients were assigned to the HIFU and halcinonide groups, respectively. The histological changes were then analyzed. After the treatments, the therapeutic effects were observed in both groups. Comparing the diagnosis and alterations in lichenoid and sclerotic patterns and in chronic inflammation, we found statistically significant differences. Furthermore, when compared with the halcinonide group, the HIFU group exhibited enhanced curative effects that were statistically significant (P = 0.039). Based on the histological evidence from this randomized, controlled trial, HIFU represents an effective method for the treatment of NNEDV.
[Mh] Termos MeSH primário: Epitélio/patologia
Ablação por Ultrassom Focalizado de Alta Intensidade
Doenças da Vulva/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Feminino
Halcinonida/uso terapêutico
Seres Humanos
Meia-Idade
Doenças da Vulva/tratamento farmacológico
Doenças da Vulva/patologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
SI86V6QNEG (Halcinonide)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170131
[Lr] Data última revisão:
170131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160519
[St] Status:MEDLINE


  2 / 46 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27170053
[Au] Autor:Liu Q; Ye Q
[Ad] Endereço:Research Center of National Health Ministry on Transplantation Medicine Engineering and Technology, 3rd Xiangya Hospital of Central South University, Changsha, Hunan, China (mainland).
[Ti] Título:Computationally Prediction of Candidate Agents for Preventing Organ Dysfunction After Brain Death.
[So] Source:Ann Transplant;21:301-10, 2016 May 12.
[Is] ISSN:2329-0358
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND Our aim was to explore the mechanism of post-transplant organ function decrease induced by brain death (BD) and discover a potential candidate drug for improving the survival and organ function after BD. MATERIAL AND METHODS The microarray data developed from the liver tissues after BD were further analyzed by bioinformatics methods. The differentially expressed genes (DEGs) were computationally predicted and the DEGs that involved biological functions were explored by gene ontology (GO) analysis. The candidate agents that could induce the reverse gene signature were predicted based on the Connectivity Map (CMap) database. RESULTS There were total 1374 DEGs, including 589 up-regulated genes and 785 down-regulated genes. Function analysis showed that DEGs were mainly enriched in biological process-related GO terms, such as regulation of transcription, DNA-dependent, inflammatory response, and regulation of phosphorus metabolic process. The down-regulated genes were significantly enriched in transcription factor activity and transcription regulator activity-related molecular function. The down-regulated GO terms exhibited close interaction with each other. CONCLUSIONS The organ function decrease may be attributed by transcription alteration, inflammation response, and metabolic alteration in liver after BD. Spaglumic acid and halcinonide may be potential drugs for preventing organ damage during the BD process.
[Mh] Termos MeSH primário: Morte Encefálica
Doadores de Tecidos
[Mh] Termos MeSH secundário: Morte Encefálica/metabolismo
Biologia Computacional
Dipeptídeos/farmacologia
Perfilação da Expressão Gênica
Ontologia Genética
Sobrevivência de Enxerto/efeitos dos fármacos
Halcinonida/farmacologia
Seres Humanos
Fígado/efeitos dos fármacos
Fígado/metabolismo
Transplante de Fígado
Análise de Sequência com Séries de Oligonucleotídeos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dipeptides); 1W8M12WXYL (isospaglumic acid); SI86V6QNEG (Halcinonide)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170130
[Lr] Data última revisão:
170130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160513
[St] Status:MEDLINE


  3 / 46 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26658258
[Au] Autor:Porcu G; Serone E; De Nardis V; Di Giandomenico D; Lucisano G; Scardapane M; Poma A; Ragnini-Wilson A
[Ad] Endereço:Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
[Ti] Título:Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRγ Receptor Activation.
[So] Source:PLoS One;10(12):e0144550, 2015.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:One of the causes of permanent disability in chronic multiple sclerosis patients is the inability of oligodendrocyte progenitor cells (OPCs) to terminate their maturation program at lesions. To identify key regulators of myelin gene expression acting at the last stages of OPC maturation we developed a drug repositioning strategy based on the mouse immortalized oligodendrocyte (OL) cell line Oli-neu brought to the premyelination stage by stably expressing a key factor regulating the last stages of OL maturation. The Prestwick Chemical Library of 1,200 FDA-approved compound(s) was repositioned at three dosages based on the induction of Myelin Basic Protein (MBP) expression. Drug hits were further validated using dosage-dependent reproducibility tests and biochemical assays. The glucocorticoid class of compounds was the most highly represented and we found that they can be divided in three groups according to their efficacy on MBP up-regulation. Since target identification is crucial before bringing compounds to the clinic, we searched for common targets of the primary screen hits based on their known chemical-target interactomes, and the pathways predicted by top ranking compounds were validated using specific inhibitors. Two of the top ranking compounds, Halcinonide and Clobetasol, act as Smoothened (Smo) agonists to up-regulate myelin gene expression in the Oli-neuM cell line. Further, RxRγ activation is required for MBP expression upon Halcinonide and Clobetasol treatment. These data indicate Clobetasol and Halcinonide as potential promyelinating drugs and also provide a mechanistic understanding of their mode of action in the pathway leading to myelination in OPCs. Furthermore, our classification of glucocorticoids with respect to MBP expression provides important novel insights into their effects in the CNS and a rational criteria for their choice in combinatorial therapies in de-myelinating diseases.
[Mh] Termos MeSH primário: Clobetasol/farmacologia
Proteínas do Citoesqueleto/metabolismo
Halcinonida/farmacologia
Proteínas Musculares/metabolismo
Bainha de Mielina/metabolismo
Receptor X Retinoide gama/metabolismo
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios/farmacologia
Linhagem Celular
Proteínas do Citoesqueleto/agonistas
Reposicionamento de Medicamentos
Expressão Gênica/efeitos dos fármacos
Immunoblotting
Camundongos
Microscopia de Fluorescência
Proteínas Musculares/agonistas
Proteína Básica da Mielina/metabolismo
Oligodendroglia/efeitos dos fármacos
Oligodendroglia/metabolismo
Receptor X Retinoide gama/genética
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Fatores de Transcrição/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Cytoskeletal Proteins); 0 (Muscle Proteins); 0 (Myelin Basic Protein); 0 (Retinoid X Receptor gamma); 0 (Smtn protein, mouse); 0 (Transcription Factors); 0 (myelin gene regulatory factor, mouse); ADN79D536H (Clobetasol); SI86V6QNEG (Halcinonide)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151215
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0144550


  4 / 46 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26367752
[Au] Autor:Draelos ZD
[Ad] Endereço:2444 N Main St, High Point, NC 27262, USA. zdraelos@northstate.net.
[Ti] Título:Stratum corneum absorption kinetics of 2 potent topical corticosteroid formulations: a pilot study.
[So] Source:Cutis;96(2):135-41, 2015 Aug.
[Is] ISSN:2326-6929
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Fluocinonide and halcinonide are class II topical corticosteroids that are indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses and generally are applied to affected skin at least twice daily. This pilot study compared the absorption kinetics of cream formulations of fluocinonide and halcinonide in the stratum corneum within a 9-hour period following application. A dermal tape-stripping protocol was used to quantify corticosteroid concentration at 6 sequential depths in the skin of 4 sites on the forearm. Halcinonide and fluocinonide were extracted from the strips and concentrations were measured using liquid chromatography-mass spectrometry. Results demonstrated the immediate absorption of fluocinonide and halcinonide into the stratum corneum within 1 hour of application followed by a sustained release of halcinonide and a steady decline of fluocinonide after peaking.
[Mh] Termos MeSH primário: Fluocinonida/farmacocinética
Glucocorticoides/farmacocinética
Halcinonida/farmacocinética
Pele/metabolismo
[Mh] Termos MeSH secundário: Administração Cutânea
Cromatografia Líquida
Fármacos Dermatológicos/administração & dosagem
Fármacos Dermatológicos/farmacocinética
Fluocinonida/administração & dosagem
Glucocorticoides/administração & dosagem
Halcinonida/administração & dosagem
Seres Humanos
Espectrometria de Massas
Projetos Piloto
Absorção Cutânea
Fita Cirúrgica
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Glucocorticoids); 2W4A77YPAN (Fluocinonide); SI86V6QNEG (Halcinonide)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:150915
[Lr] Data última revisão:
150915
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150915
[St] Status:MEDLINE


  5 / 46 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25607913
[Au] Autor:Draelos ZD
[Ti] Título:Demonstration of the biphasic release of 0.1% halcinonide cream.
[So] Source:J Drugs Dermatol;14(1):89-90, 2015 Jan.
[Is] ISSN:1545-9616
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Halcinonide in Halog Cream is formulated in a unique cream base that allows a biphasic release of this Class II steroid. Halcinonide in this product exists in two phases--a solution phase that is released immediately and a suspension phase that has a delayed release over time. The goal of this study was to evaluate this biphasic release of halcinonide into the skin using a novel noninvasive method. A dermal tape stripping protocol was used to quantify halcinonide concentration at 6 sequential depths in the skin of 4 sites on the forearms of 5 subjects. D-Squame strips were sequentially applied with consistent pressure and removed at 1, 3, 6, and 9 hours after application of halcinonide. Halcinonide was extracted from the strips and quantified using liquid chromatography mass spectrometry. The highest concentration of halcinonide was detected in strip 1 from the superficial stratum corneum with subsequent reduction in deeper stratum corneum layers as expected. The concentration increased beyond the first hour after application and demonstrated a sustained release into hour 6 before beginning declining. Similarly, the average concentration of halcinonide in strips 1 to 6 peaked at hour 1 and remained elevated for 6 hours. Data collected from the tape strips demonstrated a biphasic release of halcinonide--immediate release within 1 hour of application from the solution phase and continued, sustained release from the suspension phase following the first hour of application.
[Mh] Termos MeSH primário: Anti-Inflamatórios/administração & dosagem
Halcinonida/administração & dosagem
Absorção Cutânea
Pele/metabolismo
[Mh] Termos MeSH secundário: Administração Cutânea
Anti-Inflamatórios/farmacocinética
Cromatografia Líquida
Preparações de Ação Retardada
Liberação Controlada de Fármacos
Halcinonida/farmacocinética
Seres Humanos
Espectrometria de Massas
Creme para a Pele
Fita Cirúrgica
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Delayed-Action Preparations); SI86V6QNEG (Halcinonide)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:150122
[Lr] Data última revisão:
150122
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150122
[St] Status:MEDLINE


  6 / 46 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:24401626
[Au] Autor:Shi HH; Zhu L; Yang Y; Jin HM; Li RZ; Liang ZQ; Lang JH
[Ad] Endereço:Department of Obstetrics & Gynecology, Peking Union Medical College Hospital & Chinese Academy of Medical Sciences, Beijing 100730, China.
[Ti] Título:[Multicenter randomized clinical study of high-intensity focused ultrasound and cortical hormone in the treatment of non-neoplastic epithelial disorders of vulva].
[So] Source:Zhonghua Yi Xue Za Zhi;93(41):3291-3, 2013 Nov 05.
[Is] ISSN:0376-2491
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To evaluate the efficacy of high-intensity focused ultrasound (HIFU) and cortical hormone in the treatment of non-neoplastic epithelial disorders of vulva. METHODS: A total of 268 cases with pathologically diagnosed non-neoplastic epithelial disorders of vulva were randomly allocated into two groups of high-intensity focused ultrasound (HIFU) (n = 119) and cortical hormone (n = 124). And 25 cases became lost to follow-ups. Their signs, symptoms and quality-of-life were assessed before treatment, 1 month post-treatment and 3 months post-treatment. And the relationship was analyzed between pathologic type, age, course and efficacies. RESULTS: Their signs, symptoms and quality-of-life improved in both groups after 1 and 3 month. Compared with drug therapy, HIFU showed superior results in lesion amelioration at 1 month with significantly statistical difference and so did lesion amelioration and therapeutic effect at 3 month. And the efficacy of HIFU was better in those with >10-year disease course and pathologically diagnosed lichen sclerosus in 3 months. CONCLUSIONS: HIFU is both safe and effective in the treatment of non-neoplastic epithelial disorders of vulva.
[Mh] Termos MeSH primário: Halcinonida/uso terapêutico
Terapia por Ultrassom
Doenças da Vulva/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Meia-Idade
Estudos Prospectivos
Resultado do Tratamento
Terapia por Ultrassom/métodos
Adulto Jovem
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
SI86V6QNEG (Halcinonide)
[Em] Mês de entrada:1409
[Cu] Atualização por classe:140109
[Lr] Data última revisão:
140109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140110
[St] Status:MEDLINE


  7 / 46 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22712560
[Au] Autor:Clijsen R; Baeyens JP; Barel AO; Clarys P
[Ad] Endereço:Faculty of Physical Education and Physiotherapy, Vrije Universiteit Brussel, Brussels, Belgium. r.clijsen@physioschule.ch
[Ti] Título:Influence of the timing of ultrasound application on the penetration of corticosteroids.
[So] Source:Skin Res Technol;19(1):e279-82, 2013 Feb.
[Is] ISSN:1600-0846
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The application of ultrasound to enhance the transdermal transport of drugs is often referred to as 'sonophoresis'. In physiotherapy sonophoresis is applied to the skin through two different procedures: (1) the pre-treatment procedure where the skin is treated with ultrasound irradiation prior to the drug application and (2) a simultaneous treatment mode, where the skin is treated with ultrasound during the application of the pharmacologic substance. The aim of this study was to compare the bioavailability of halcinonide in the stratum corneum comparing the ultrasound pre-treatment vs. the simultaneous treatment method. METHODS: The effect of pre and simultaneous ultrasound treatment (1 MHz, 1 W/cm(2)) was evaluated on the halcinonide blanching response using tristimulus colorimetry 2 h after the initial application. RESULTS: Within the evaluation period, only the ultrasound pre-treatment method resulted in a significant blanching response. CONCLUSION: Timing of the ultrasound application seems to influence the availability and percutaneous penetration process and should be taken into account when estimating the ultrasound enhancing effect.
[Mh] Termos MeSH primário: Corticosteroides/farmacocinética
Sistemas de Liberação de Medicamentos/métodos
Epiderme/diagnóstico por imagem
Epiderme/metabolismo
Halcinonida/farmacocinética
Ultrassom/métodos
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Anti-Inflamatórios/farmacocinética
Feminino
Seres Humanos
Masculino
Absorção Cutânea
Ultrassonografia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Anti-Inflammatory Agents); SI86V6QNEG (Halcinonide)
[Em] Mês de entrada:1306
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120621
[St] Status:MEDLINE
[do] DOI:10.1111/j.1600-0846.2012.00639.x


  8 / 46 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:20439738
[Au] Autor:Wang J; Lu J; Bond MC; Chen M; Ren XR; Lyerly HK; Barak LS; Chen W
[Ad] Endereço:Departments of Medicine, Surgery, and Cell Biology, Duke University Medical Center, Durham, NC 27710, USA.
[Ti] Título:Identification of select glucocorticoids as Smoothened agonists: potential utility for regenerative medicine.
[So] Source:Proc Natl Acad Sci U S A;107(20):9323-8, 2010 May 18.
[Is] ISSN:1091-6490
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Regenerative medicine holds the promise of replacing damaged tissues largely by stem cell activation. Hedgehog signaling through the plasma membrane receptor Smoothened (Smo) is an important process for regulating stem cell proliferation. The development of Hedgehog-related therapies has been impeded by a lack of US Food and Drug Administration (FDA)-approved Smo agonists. Using a high-content screen with cells expressing Smo receptors and a beta-arrestin2-GFP reporter, we identified four FDA-approved drugs, halcinonide, fluticasone, clobetasol, and fluocinonide, as Smo agonists that activate Hedgehog signaling. These drugs demonstrated an ability to bind Smo, promote Smo internalization, activate Gli, and stimulate the proliferation of primary neuronal precursor cells alone and synergistically in the presence of Sonic Hedgehog protein. Halcinonide, fluticasone, clobetasol, and fluocinonide provide an unprecedented opportunity to develop unique clinical strategies to treat Hedgehog-dependent illnesses.
[Mh] Termos MeSH primário: Glucocorticoides/farmacologia
Proteínas Hedgehog/metabolismo
Receptores Acoplados a Proteínas-G/agonistas
Medicina Regenerativa/métodos
Transdução de Sinais/fisiologia
Células-Tronco/fisiologia
[Mh] Termos MeSH secundário: Androstadienos/farmacologia
Arrestinas
Western Blotting
Linhagem Celular
Proliferação Celular
Clobetasol/farmacologia
Fluocinonida/farmacologia
Fluticasona
Proteínas de Fluorescência Verde
Halcinonida/farmacologia
Seres Humanos
Estrutura Molecular
Receptor Smoothened
Células-Tronco/metabolismo
beta-Arrestinas
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Androstadienes); 0 (Arrestins); 0 (Glucocorticoids); 0 (Hedgehog Proteins); 0 (Receptors, G-Protein-Coupled); 0 (SMO protein, human); 0 (Smoothened Receptor); 0 (beta-Arrestins); 147336-22-9 (Green Fluorescent Proteins); 2W4A77YPAN (Fluocinonide); ADN79D536H (Clobetasol); CUT2W21N7U (Fluticasone); SI86V6QNEG (Halcinonide)
[Em] Mês de entrada:1007
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100505
[St] Status:MEDLINE
[do] DOI:10.1073/pnas.0910712107


  9 / 46 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19397627
[Au] Autor:Thormann H; Kollander M; Andersen KE
[Ad] Endereço:Department of Dermatology, Odense University Hospital, University of Southern Denmark, Odense C, Denmark. henrik.thormann@ouh.regionsyddanmark.dk
[Ti] Título:Allergic contact dermatitis from dichlorobenzyl alcohol in a patient with multiple contact allergies.
[So] Source:Contact Dermatitis;60(5):295-6, 2009 May.
[Is] ISSN:1600-0536
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Álcoois Benzílicos/toxicidade
Dermatite Alérgica de Contato/etiologia
Conservantes Farmacêuticos/toxicidade
[Mh] Termos MeSH secundário: Idoso
Anti-Inflamatórios/efeitos adversos
Dermatite Alérgica de Contato/diagnóstico
Álcoois Graxos/toxicidade
Halcinonida/efeitos adversos
Seres Humanos
Masculino
Testes do Emplastro
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Benzyl Alcohols); 0 (Fatty Alcohols); 0 (Preservatives, Pharmaceutical); 1NKX3648J9 (dichlorobenzyl alcohol); 2KR89I4H1Y (stearyl alcohol); SI86V6QNEG (Halcinonide)
[Em] Mês de entrada:1105
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090429
[St] Status:MEDLINE
[do] DOI:10.1111/j.1600-0536.2009.01533.x


  10 / 46 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:12890226
[Au] Autor:Broberg A; Gruvberger B; Isaksson M
[Ti] Título:Dead Sea extract sold under-the-counter.
[So] Source:Br J Dermatol;149(1):206-7, 2003 Jul.
[Is] ISSN:0007-0963
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Terapias Complementares
Dermatite/tratamento farmacológico
Fármacos Dermatológicos/administração & dosagem
Medicamentos sem Prescrição/administração & dosagem
Cloreto de Sódio/uso terapêutico
[Mh] Termos MeSH secundário: Balneologia
Fármacos Dermatológicos/efeitos adversos
Contaminação de Medicamentos
Feminino
Glucocorticoides/administração & dosagem
Halcinonida/administração & dosagem
Halcinonida/análise
Seres Humanos
Águas Minerais
Medicamentos sem Prescrição/efeitos adversos
Triancinolona/administração & dosagem
Triancinolona/análise
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Dermatologic Agents); 0 (Glucocorticoids); 0 (Mineral Waters); 0 (Nonprescription Drugs); 1ZK20VI6TY (Triamcinolone); 451W47IQ8X (Sodium Chloride); SI86V6QNEG (Halcinonide)
[Em] Mês de entrada:0310
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:030802
[St] Status:MEDLINE



página 1 de 5 ir para página              
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde